Telix Pharmaceuticals Gross Profit vs. Shares Outstanding
| TLPPF Stock | USD 16.00 0.82 5.40% |
For Telix Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Telix Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Telix Pharmaceuticals Limited utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Telix Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Telix Pharmaceuticals Limited over time as well as its relative position and ranking within its peers.
Telix |
Telix Pharmaceuticals Shares Outstanding vs. Gross Profit Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Telix Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Telix Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Telix Pharmaceuticals Limited is currently regarded as top stock in gross profit category among its peers. It is rated fourth in shares outstanding category among its peers creating about 62.80 of Shares Outstanding per Gross Profit. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Telix Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Telix Shares Outstanding vs. Gross Profit
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Telix Pharmaceuticals |
| = | 5.05 M |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Telix Pharmaceuticals |
| = | 317.02 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Telix Shares Outstanding Comparison
Telix Pharmaceuticals is currently under evaluation in shares outstanding category among its peers.
Telix Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Telix Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Telix Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Telix Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Telix Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company was founded in 2015 and is headquartered in North Melbourne, Australia. Telix Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Telix Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Telix Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Telix Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Telix Pharmaceuticals' important profitability drivers and their relationship over time.
Use Telix Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Telix Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Telix Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Telix Pharmaceuticals Pair Trading
Telix Pharmaceuticals Limited Pair Trading Analysis
The ability to find closely correlated positions to Telix Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Telix Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Telix Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Telix Pharmaceuticals Limited to buy it.
The correlation of Telix Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Telix Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Telix Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Telix Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Telix Pharmaceuticals position
In addition to having Telix Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Debt ETFs Thematic Idea Now
Broad Debt ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Debt ETFs theme has 233 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Debt ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Telix Pink Sheet
When determining whether Telix Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Telix Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Telix Pharmaceuticals Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Telix Pharmaceuticals Limited Stock:Check out World Market Map. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
To fully project Telix Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Telix Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Telix Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.